Healthcare Professional

Event Details

Wednesday
December 10, 2025
6:00pm - 8:00pm EST

Click Here to Register

Program contact: Kristen Parker
[email protected] | 317.860.3845

*Pre-Registration Required

Live In-Person Event

Join us for a valuable dialogue about blood cancer, where attendees will gain a greater understanding about living with, through, and beyond their diagnosis. Local healthcare professionals will provide their expertise and insights on a range of topics.

Participants will learn about:

• The latest treatments on the horizon
• How to approach treatment decision making
• Strategies for navigating life during and after treatment
• Blood Cancer United and local resources to help you flourish in survivorship

Come with your questions and be part of an engaging, informative discussion! We encourage you to bring your support system to join us for an evening of free education, support, and community connection.

Speakers

Don A. Stevens, MD
Hematology Oncology
Norton Cancer Institute
Panelist

Kaley Pagan,PharmD, BCOP
Clinical Pharmacy Specialist
Norton Cancer Institute
Panelist
 

Katie Fernandez,MSSW, CSW
Oncology Social Worker
Baptist Health Louisville
Panelist

Kayla Wilson, APRN,FNP-C, AOCNP
Nurse Practitioner
Norton Cancer Institute
Panelist

Christina White,PharmD, MBA, BCPS
Pharmacist & Caregiver
Moderator

If, for any reason, you are not comfortable attending an in-person event, please find our virtual education opportunities at www.bloodcancerunited.org/programs.

Event Details

Wednesday, November 12, 2025
1:00 PM – 2:00 PM ET
12:00 PM – 1:00 PM CT
11:00 AM – 12:00 PM MT
10:00 AM – 11:00 AM PT

Program Slides:
Download

Format
Live Interactive Webinar

Target Audience
This activity is intended for hematologists-oncologists, medical oncologists, PAs, NPs, nurses, and other healthcare professionals engaged in the care of patients with Chronic Lymphocytic Leukemia (CLL).

Description
This webinar will provide a clinical update on chronic lymphocytic leukemia (CLL). Expert faculty will review the latest therapies, including BTK inhibitors and CAR T-cell therapy, share guidance on patient selection, and discuss strategies for treatment management, toxicity monitoring, and long-term survivorship care.

Learning Objectives
After completing this activity, the participant should be better able to:

• Explain treatment options including an overview of the latest developments in therapy
• Identify patients who are candidates for newly approved therapies including BTK inhibitors, alone or in combination, and CAR T-cell therapy
• Explain the HCP’s role in preparing the patient for therapy, administering treatment, monitoring for and managing side effects
• Discuss long-term follow up and survivorship care planning

Faculty
Inhye Ahn, MD
Associate Director, Chronic Lymphocytic Leukemia Center
Senior Physician
Assistant Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute 
Boston, MA

Lauren Berger, MPH
Blood Cancer United
Washington, DC

Corinne Hoffman, MS, APRN-CNP, AOCNP
Nurse Practitioner - Hematology Oncology
The James Comprehensive Cancer Center
The Ohio State University
Columbus, OH

Kerry Rogers, MD 
Associate Professor 
Division of Hematology, Department of Internal Medicine
The James Comprehensive Cancer Center 
The Ohio State University
Columbus, OH

Continuing Education Information
In support of improving patient care, this activity has been planned and implemented by Blood Cancer United and Medical Learning Institute Inc.  Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™.  
Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registered Nursing Credit Designation
Approval for nurses has been obtained by the National Office of Blood Cancer United under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

Method of Participation
There are no fees for participating in or receiving credits for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Learners must participate in the entire CE activity, complete, and submit the evaluation form to earn credit. Once submitted, the certificate will be generated. If you have questions regarding the receipt of your certificate, please contact via email at [email protected].

Providers

This activity is provided by Blood Cancer United and Medical Learning Institute Inc.

Supporters

This activity is supported by independent medical education grants from AbbVie Inc. and AstraZeneca Pharmaceuticals.

For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: [email protected].

Click here to participate

Live, interactive, case based discussion with audience input - free CME/CE series

CLICK HERE TO PARTICIPATE

Session 1: Rapid Diagnosis, Risk Stratification, and Induction Therapies – Recording(Not accredited)

Session 2: Evolving Treatment in Cell Therapy and Transplant – November 19, 2025, 5:00 pm ET – 6:00 pm ET

Session 3: Coordinated Care from Treatment to Survivorship – January 28, 2026, 5:00 pm ET – 6:00 pm ET

For each live session you participate in, 1.0 credit/contact hour will be provided, for a total of 3.0possible credits.  Participation at all three live sessions is encouraged but not required to obtain CME/CE credits. 

Description:

The Project ECHO model is designed to create a shared learning space for healthcare professionals through a series of educational sessions, fostering peer engagement and disseminating best practices in community care. Rapid advances in the treatment of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), can make treatment decisions challenging. This virtual series will help providers stay up to date on the latest in disease-specific indications, treatment with HCT and cell therapy, and post-treatment monitoring and care coordination to improve patient outcomes.

Target Audience:

This activity is intended for hematology-oncology providers, including physicians, APPs and nurses who want to learn more about managing, treating, and monitoring patients with acute leukemias including those undergoing transplant and cell therapy.

Learning Objectives:

After completing this activity, the participant should be better able to:

Session 1:

• Describe disease-specific features and indications of acute leukemias, including subtype classification

• Identify tests used to diagnose acute leukemias

• Examine therapeutic options for induction

Session 2:

• Examine the appropriate treatments for acute leukemias and timing, including allogeneic HCT and CAR T-cell therapy

• Identify and manage treatment related side effects and treatment related complications

Session 3:

• Discuss post-treatment monitoring of long-term and late effects and surveillance strategies for detecting relapse post allogeneic HCT and CAR T-cell therapy

• Identify best practices in care coordination between hematology-oncology, transplant, and otherproviders involved in the care of patients

Faculty:

Alison Loren, MD, MSCE (chair/moderator, sessions 1, 2, 3)
Chief, Division of Hematology/Oncology
Director, Blood and Marrow Transplantation
C. Willard Robinson Professor of Hematology/Oncology
University of Pennsylvania
Philadelphia, PA

Shernan Holtan, MD (chair/moderator, sessions 1, 2, 3)
Chief, Blood and Marrow Transplantation Section
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, NY

Session 1

Alice S. Mims, MD, MSCR
Acute Leukemia Research Section Head
Associate Division Director Clinical Research
Professor of Medicine
The Ohio State University Comprehensive Cancer Center
Columbus, OH

Courtney Bellomo, MD
Hematology 
New York Oncology Hematology
Albany, NY 

Meghan McGrath, MSN, RN, AGACNP-BC
Clinical Trial Nurse Navigator
Blood Cancer United
Washington, DC

Session 2

Clark Alsfeld, MD
Attending Physician
Ochsner MD Anderson Cancer Center
Ochsner Health
New Orleans, LA 

Alice S. Mims, MD, MSCR
Acute Leukemia Research Section Head
Associate Division Director Clinical Research
Professor of Medicine
The Ohio State University Comprehensive Cancer Center
Columbus, OH 

Darci Zblewski, APN, C-NP
Consultant
Blood Cancer United
Washington, DC

Session 3

Clark Alsfeld, MD
Attending Physician
Ochsner MD Anderson Cancer Center
Ochsner Health
New Orleans, LA 

Courtney Bellomo, MD
Hematology
New York Oncology Hematology
Albany, NY

Ankita Shah, FNP-BC
Access Partnership Consultant
NMDP
Minneapolis, MN

Continuing Education Information

In support of improving patient care, this activity has been planned and implemented by Blood Cancer United and Medical Learning Institute Inc. Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registered Nursing Designation 
Approval for nurses has been obtained by the National Office of Blood Cancer United under Provider Number CEP 5832 to award 1.0 continuing education contact hours through the California Board of Registered Nursing. 

Providers
This activity is provided by Blood Cancer United, NMDP and Medical Learning Institute Inc, in collaboration with Project ECHO.

There is no commercial support for this activity.

For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: [email protected].

Click here to participate